The DRCRnet protocol W6 explored the potential use of anti-VEGF injections at earlier stages of retinopathy to prevent DR progression in eyes without DMO, finding 2-year PDR cumulative probability of 13.5% in the aflibercept treated group. Here, VEGFA is linked to retinal disorder.